These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 28259822

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH, Chen LY, Lin YC, Shih JY, Lin YC, Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, Fang JM, Chen CC.
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [Abstract] [Full Text] [Related]

  • 23. SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting β-catenin and epithelial to mesenchymal transition in lung cancer.
    Tripathi SK, Biswal BK.
    Life Sci; 2021 Jul 15; 277():119608. PubMed ID: 33989664
    [Abstract] [Full Text] [Related]

  • 24. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
    Togashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.
    J Thorac Oncol; 2015 Jan 15; 10(1):93-101. PubMed ID: 25384171
    [Abstract] [Full Text] [Related]

  • 25. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ, Feng JF.
    Oncol Rep; 2013 May 15; 29(5):1975-82. PubMed ID: 23440266
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
    Bae SY, Hong JY, Lee HJ, Park HJ, Lee SK.
    Oncotarget; 2015 Apr 30; 6(12):10146-60. PubMed ID: 25760142
    [Abstract] [Full Text] [Related]

  • 30. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.
    Li Y, Yang Z, Li W, Xu S, Wang T, Wang T, Niu M, Zhang S, Jia L, Li S.
    Oncotarget; 2016 Feb 09; 7(6):6748-64. PubMed ID: 26745678
    [Abstract] [Full Text] [Related]

  • 31. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
    Bai XY, Zhang XC, Yang SQ, An SJ, Chen ZH, Su J, Xie Z, Gou LY, Wu YL.
    PLoS One; 2016 Feb 09; 11(3):e0149370. PubMed ID: 26943330
    [Abstract] [Full Text] [Related]

  • 32. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
    Tsai CM, Chen JT, Chiu CH, Lai CL, Hsiao SY, Chang KT.
    Lung Cancer; 2013 Nov 09; 82(2):305-12. PubMed ID: 24055492
    [Abstract] [Full Text] [Related]

  • 33. Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.
    Li B, Yao Z, Wan Y, Lin D.
    Oncotarget; 2016 Nov 22; 7(47):77342-77347. PubMed ID: 27816965
    [Abstract] [Full Text] [Related]

  • 34. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
    Yoo SB, Kim YJ, Kim H, Jin Y, Sun PL, Jheon S, Lee JS, Chung JH.
    Ann Surg Oncol; 2013 Dec 22; 20 Suppl 3():S545-52. PubMed ID: 23579873
    [Abstract] [Full Text] [Related]

  • 35. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY, Zhao MB, Zhuang GB, Li PP.
    Lung Cancer; 2012 Jan 22; 75(1):30-7. PubMed ID: 21757251
    [Abstract] [Full Text] [Related]

  • 36. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y, Fan X, Li W, Ping W, Deng Y, Fu X.
    Biochem Biophys Res Commun; 2014 Mar 28; 446(1):179-86. PubMed ID: 24582749
    [Abstract] [Full Text] [Related]

  • 37. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
    Jung SK, Lee MH, Lim DY, Lee SY, Jeong CH, Kim JE, Lim TG, Chen H, Bode AM, Lee HJ, Lee KW, Dong Z.
    Mol Carcinog; 2015 Apr 28; 54(4):322-31. PubMed ID: 24974831
    [Abstract] [Full Text] [Related]

  • 38. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM, Jang JY, Choi YR, Kim HR, Cho BC, Lee HW.
    Lung Cancer; 2015 Nov 28; 90(2):175-81. PubMed ID: 26342551
    [Abstract] [Full Text] [Related]

  • 39. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY.
    Clin Cancer Res; 2007 May 01; 13(9):2795-803. PubMed ID: 17473213
    [Abstract] [Full Text] [Related]

  • 40. Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs.
    Nakata A, Yoshida R, Yamaguchi R, Yamauchi M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M, Kimura T, Nokihara H, Higashiyama M, Kondoh K, Nishihara H, Tojo A, Yano S, Miyano S, Gotoh N.
    Sci Rep; 2015 Aug 13; 5():13076. PubMed ID: 26268703
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.